Factors associated with PNR to CD19 CAR T cells

Risk factorResponse rates
Prior blinatumomab 64.5% in blinatumomab nonresponders vs 92.9% in blinatumomab responders vs 93.5% in blinatumomab-untreated patients6  
Bone marrow disease burden 73% in HB (>5% blasts) vs 98% in low disease burden vs 100% in undetectable7  
Cytogenetics 93% in high risk vs 86% in intermediate risk vs 98% in favorable risk9  
Apheresed peripheral blood T cells 28.6% when CD8 cells express LAG3 ≥0.745% AND TNF-α <25.283% vs 100% for all others10  
CD19 isoforms The presence of increased transcripts with CD19 isoforms skipping exon 2 yield nonresponse1,11  
Bone marrow epigenetics Hypermethylation at genes known to be targets of PRC2 repression in embryonic stem cells yields nonresponse1  
Risk factorResponse rates
Prior blinatumomab 64.5% in blinatumomab nonresponders vs 92.9% in blinatumomab responders vs 93.5% in blinatumomab-untreated patients6  
Bone marrow disease burden 73% in HB (>5% blasts) vs 98% in low disease burden vs 100% in undetectable7  
Cytogenetics 93% in high risk vs 86% in intermediate risk vs 98% in favorable risk9  
Apheresed peripheral blood T cells 28.6% when CD8 cells express LAG3 ≥0.745% AND TNF-α <25.283% vs 100% for all others10  
CD19 isoforms The presence of increased transcripts with CD19 isoforms skipping exon 2 yield nonresponse1,11  
Bone marrow epigenetics Hypermethylation at genes known to be targets of PRC2 repression in embryonic stem cells yields nonresponse1  

TNF-α, tumor necrosis factor α.

or Create an Account

Close Modal
Close Modal